Advanced searches left 3/3

Elbasvir and Grazoprevir - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 20 January 2022

* If you want to update the article please login/register

"Real World" Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring

A significant section of the medical treatment provided to HD patients is by Nephrologists and HD team. Supply standards for implementation and surveillance of DAA therapy in HD patients with HCV 2. Patients that meet addition criteria without exemption standards be designated therapy with Zepatier with or without Ribavirin according to following routine: Genotype 1a - therapy naive without NS5A polymorphism - Zepatier one tablet computer daily for 12 weeks Genotype 1a - treatment naiive with NS5A polymorphism - Zepatier one tablet everyday and ribavirin daily for 16 weeks Genotype 1b-treatment naive - Zepatier one day-to-day for 12 weeks Genotype 1a or 1b - prior therapy with INF or HCV NS3/4A protease prevention - Zepatier and ribavirin each once daily for 12 weeks Genotype 4 - treatment ignorant - Zepatier one day-to-day for 12 weeks Genotype 4 -previous treatment - Zepatier and ribavirin each once each day for 16 weeks Baseline/Screening Testing: 1. For patients with HCV genotype 1a, test fro NS5A anomaly Treatment of HIV/HCV co-infected patients will be carried out in collaboration with the HIV dealing with medical professional to establish if any adjustments in the HIV drug routines will be called for Testing/Evaluations during Active DAA Treatment - 1. Clinical Pharmacologoy assessment 12 weeks post treatment for adverse occasions 3. patients who attain sustained viral remission at 12 weeks will be identified in HD records as HCV abdominal muscle positive yet HCV viral tons RNA adverse.

Source link: https://clinicaltrials.gov/ct2/show/NCT03365635

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions